SODIUM NITRITE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sodium Nitrite, and what generic alternatives are available?
Sodium Nitrite is a drug marketed by Hope Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has thirty patent family members in fifteen countries.
The generic ingredient in SODIUM NITRITE is sodium nitrite. There are one thousand four hundred and seventy-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium nitrite profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Nitrite
A generic version of SODIUM NITRITE was approved as sodium nitrite by HOPE PHARMS on February 14th, 2012.
US Patents and Regulatory Information for SODIUM NITRITE
SODIUM NITRITE is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SODIUM NITRITE is ⤷ Start Trial.
This potential generic entry date is based on patent 9,687,506.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hope Pharms | SODIUM NITRITE | sodium nitrite | SOLUTION;INTRAVENOUS | 203922-001 | Feb 14, 2012 | RX | Yes | Yes | 9,687,506 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hope Pharms | SODIUM NITRITE | sodium nitrite | SOLUTION;INTRAVENOUS | 203922-001 | Feb 14, 2012 | RX | Yes | Yes | 8,568,793 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SODIUM NITRITE
When does loss-of-exclusivity occur for SODIUM NITRITE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 10213743
Patent: Sodium nitrite-containing pharmaceutical compositions
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 52129
Patent: COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷ Start Trial
Croatia
Patent: 0191516
Estimated Expiration: ⤷ Start Trial
Patent: 0211077
Estimated Expiration: ⤷ Start Trial
Cyprus
Patent: 24426
Estimated Expiration: ⤷ Start Trial
Denmark
Patent: 95834
Estimated Expiration: ⤷ Start Trial
Patent: 69237
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 95834
Patent: COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷ Start Trial
Patent: 69237
Patent: COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷ Start Trial
Patent: 62007
Patent: COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷ Start Trial
Hungary
Patent: 44781
Estimated Expiration: ⤷ Start Trial
Patent: 55250
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 89519
Estimated Expiration: ⤷ Start Trial
Patent: 59297
Estimated Expiration: ⤷ Start Trial
Patent: 12517474
Patent: 亜硝酸ナトリウムを含む医薬組成物
Estimated Expiration: ⤷ Start Trial
Patent: 15199764
Patent: 亜硝酸ナトリウムを含む医薬組成物 (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷ Start Trial
Lithuania
Patent: 95834
Estimated Expiration: ⤷ Start Trial
Patent: 69237
Estimated Expiration: ⤷ Start Trial
Poland
Patent: 95834
Estimated Expiration: ⤷ Start Trial
Patent: 69237
Estimated Expiration: ⤷ Start Trial
Portugal
Patent: 95834
Estimated Expiration: ⤷ Start Trial
Patent: 69237
Estimated Expiration: ⤷ Start Trial
Slovenia
Patent: 95834
Estimated Expiration: ⤷ Start Trial
Patent: 69237
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 43303
Estimated Expiration: ⤷ Start Trial
Patent: 80500
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SODIUM NITRITE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2880500 | ⤷ Start Trial | |
| Cyprus | 1121939 | ⤷ Start Trial | |
| Japan | 2012517474 | 亜硝酸ナトリウムを含む医薬組成物 | ⤷ Start Trial |
| San Marino | T201900476 | ⤷ Start Trial | |
| Croatia | P20191516 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SODIUM NITRITE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2666774 | CA 2020 00037 | Denmark | ⤷ Start Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 0290047 | SPC/GB97/078 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522 |
| 1856135 | LUC00153 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113 |
| 2822954 | 1890030-8 | Sweden | ⤷ Start Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
| 2932970 | SPC/GB18/041 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Investment Scenario and Fundamentals Analysis for Sodium Nitrite
More… ↓
